Esomeprazole/naproxen

Drug Profile

Esomeprazole/naproxen

Alternative Names: esomeprazole magnesium trihydrate/naproxen; Naproxen/esomeprazole; naproxen/esomeprazole magnesium trihydrate; PN-400; Vimovo

Latest Information Update: 07 Jul 2017

Price : $50

At a glance

  • Originator AstraZeneca; POZEN
  • Developer Aralez Pharmaceuticals Inc.; AstraZeneca
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 27 Jun 2017 United States District Court for the District of New Jersey upholds validity of patent infringement lawsuit filed against Dr. Reddy's Laboratories, Lupin Pharmaceuticals, Mylan Pharmaceuticals and Mylan Laboratories by Horizon Pharma for infringing two Horizon Pharma patents covering naproxen/esomeprazole magnesium in USA
  • 30 Mar 2017 Horizon Pharma receives patent allowance from USPTO for naproxen/esomeprazole
  • 13 Mar 2017 Aralez Pharmaceuticals has patent protection for Esomeprazole/naproxen in USA, Australia, Canada, Europe, Eurasia, Israel, Mexico, Japan and Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top